MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - May 19, 2011) -
MorphoSys AG /
MorphoSys Reports Promising Pre-clinical Data for MOR202
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Combination Studies to be Presented at Annual Meeting of the American
Clinical Oncology (ASCO)
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today
promising pre-clinical data on its proprietary drug candidate MOR202, a
derived, fully human anti-CD38 antibody. Studies showed that by combining
with each of two approved drugs for the treatment of multiple myeloma, the
cancer activity of the antibody could be enhanced. The effects were seen
vitro and in vivo models of the disease. The pre-clinical data will be
at the 2011 Annual Meeting of the American Society of Clinical Oncology
to be held June 3-7, 2011, at the McCormick Place Convention Center in
"The synergistic effects that we've seen in pre-clinical studies are
encouraging and point towards a potential clinical use of MOR202,"
Arndt Schottelius, Chief Development Officer of MorphoSys AG. "We look
to evaluating MOR202 in a phase 1/2a clinical trial in patients with
myeloma, which we expect to start shortly."
Multiple myeloma is the second most common hematologic cancer and the
common cancer to involve bone, resulting in severe pain and bone fractures
the course of the disease. In vitro, MOR202 mediates the killing of
myeloma cells by antibody-dependent cellular cytotoxicity (ADCC). In
with the drug bortezomib (Velcade®), MOR202 displayed an
cytotoxic effect on multiple myeloma cells. The drug lenalidomide
synergistically enhanced MOR202 activity on multiple myeloma cells by
mechanisms, including direct cytotoxicity, activation of effector
increased CD38 expression levels on the tumor cell surface.
In an in vivo mouse model of multiple myeloma, MOR202 reduces tumor load as
as tumor-mediated bone destruction. In this model, MOR202 in combination
either bortezomib or lenalidomide completely abolished bone destruction
synergistic manner. These findings support further investigation of
combination regimens in clinical trials.
The abstract is available on www.asco.org.
MorphoSys is an independent biotechnology company that develops novel
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical
MorphoSys has created a pipeline of more than 60 drug candidates. The
expanding its drug pipeline by adding new partnered programs, and by
portfolio of fully-owned therapeutic antibodies. For its proprietary
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information,
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®
and RapMAT® are
registered trademarks of MorphoSys; arYla™ is a trademark of MorphoSys.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE